Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

July 8, 2022

Study Completion Date

July 8, 2022

Conditions
Benign Prostatic Hyperplasia
Interventions
DEVICE

Composite Steep-pulse Treatment Device

Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia

DRUG

Tamsulosin Hydrochloride Capsules

Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia

Trial Locations (1)

200000

Remd Medical Technology, Shanghai

All Listed Sponsors
collaborator

RenJi Hospital

OTHER

collaborator

Dongfang Hospital Affiliated to Tongji University

OTHER

collaborator

Shanghai Pudong Hospital

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Ningbo No.2 Hospital

OTHER

collaborator

Shangdong Yiyuan Hospital

UNKNOWN

collaborator

Tongji Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Hunan Provincial People's Hospital

OTHER

lead

REMD Medical Technology

INDUSTRY

NCT05531344 - Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter